Neuropathologic substrates of Parkinson disease dementia

2012529 citationsJournal Article

Authors

David J. Irwin · Parkinson's and Movement Disorder Institute

Matthew T. White · University of Pennsylvania

Jon B. Toledo · Institute on Aging

Sharon X. Xie · University of Pennsylvania

John Robinson · Institute on Aging

Vivianna M. Van Deerlin · Institute on Aging

Virginia M.‐Y. Lee

Abstract

CLB/LN pathology is the most significant correlate of dementia in PD. Additionally, APOE4 genotype may independently influence the risk of dementia in PD. AD pathology was abundant in a subset of patients, and may modify the clinical phenotype. Thus, therapies that target α-synuclein, tau, or amyloid β could potentially improve cognitive performance in PD.

Topics & Keywords

Parkinson's Disease Mechanisms and Treatments Alzheimer's disease research and treatments Neurological disorders and treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Neurology

Volume 72, Issue 4, pp. 587-598

DOI: 10.1002/ana.23659

Field-Weighted Citation Impact: 23.41